04Nov 2015
endocrine society

J Clin Endocrinol Metab. 2015 Nov;100(11):4208-14. doi: 10.1210/jc.2015-2829. Epub 2015 Sep 10

CONCLUSIONS: These findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone loss after teriparatide.

Autor: Cohen A, Kamanda-Kosseh M, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, Bucovsky M, Stubby J, Shane E.
04Oct 2015
wiley-logo

J Bone Miner Res. 2015 Oct;30(10):1758-66. doi: 10.1002/jbmr.2515. Epub 2015 May 10.

In summary, for older men and women, calcium intakes of up to 1348 (316) mg/d from food were associated with decreased risks for fracture, non-fatal CVD, stroke, and all-cause mortality.

Autor: WILE Khan B, Nowson CA, Daly RM, English DR, Hodge AM, Giles GG, Ebeling PR.
04Oct 2015
wiley-logo

J Bone Miner Res. 2015 Oct;30(10):1747-53. doi: 10.1002/jbmr.2531.

A position paper of the National Bone Health Alliance recently recommended that diagnostic criteria for osteoporosis be redefined. We review the merits and demerits of this proposal and argue that the operational bone mineral density (BMD)-based definition be retained while clarity is brought to bear on the distinction between diagnostic and intervention thresholds.

Autor: Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD.
04Oct 2015
Springer

Osteoporos Int. 2015 Oct;26(10):2479-89. doi: 10.1007/s00198-015-3164-4. Epub 2015 May 28.

These data extend the real-world evidence regarding persistence with and adherence to denosumab, both of which are critical for favorable clinical outcomes, including fracture risk reduction.

Autor: Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G, Kalouche-Khalil L, Fahrleitner-Pammer A.
04Oct 2015
Springer

Osteoporos Int. 2015 Oct;26(10):2401-11. doi: 10.1007/s00198-015-3253-4. Epub 2015 Aug 18.

These data from the Swedish Prescribed Drug Register and literature review suggest that persistence was higher with denosumab than with oral bisphosphonates.

Autor: Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, et al.
04Oct 2015
bone logo

Bone. 2015 Oct 20;83:35-47. doi: 10.1016/j.bone.2015.10.008. [Epub ahead of print]

CONCLUSIONS: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is modulated by FGF23. Since both proteins play important roles in the bone and cardiovascular pathology, these results add new pieces to the puzzling relationship between bone and vascular pathology, in particular in CKD patients, prompting future investigations in this field.

Autor: Mattinzoli D, Rastaldi MP, Ikehata M, Armelloni S, Pignatari C, Giardino LA, Li M, Alfieri CM, Regalia A, Riccardi D, Messa P.
04Oct 2015
Springer

Curr Osteoporos Rep. 2015 Oct;13(5):287-301. doi: 10.1007/s11914-015-0282-z.

Among women 50-64 years old, a Fracture Risk Assessment Tool (FRAX) threshold ≥9.3 % had a sensitivity of 33 % for identifying BMD T-score ≤-2.5 and 26 % for predicting major osteoporotic fracture (MOF). For predicting MOF, sensitivity was higher for SCORE and Osteoporosis Self-assessment Tool equation (OST), and higher in women ≥65 years old. For predicting BMD T-score ≤-2.5 in women ≥65 years old, the sensitivities of SCORE; ORAI; and Age, Body Size, No Estrogen (ABONE) were very high. No optimal osteoporosis risk assessment tool is available for identifying low BMD and MOF risk.

Autor: Crandall CJ.